FDA Approves First Generic Abilify

Share this content:
FDA Approves First Generic Abilify
FDA Approves First Generic Abilify

WEDNESDAY, April 29, 2015 (HealthDay News) -- The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.

License to produce the drug in multiple strengths was approved for Alembic Pharmaceuticals, Hetero Labs, Teva Pharmaceuticals, and Torrent Pharmaceuticals, the agency said in a news release.

As with other atypical antipsychotic drugs, generic Abilify's label will contain the FDA's most stringent boxed warning that the medication poses an increased risk of death among older people with dementia-related psychosis. The label also warns of an increased risk of suicidal thinking and behavior among children, teens, and young adults.

The most common side effects of the drug are nausea, vomiting, constipation, headache, dizziness, akathisia, anxiety, insomnia, and restlessness.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Zika, West Nile Cases Reported in Alabama

Zika, West Nile Cases Reported in Alabama

State health officials note that Zika hasn't been transmitted locally

TBI Linked to Increased Suicide Risk

TBI Linked to Increased Suicide Risk

Increased suicide risk with one, two, and three or more medical contacts for traumatic brain injury

Triple Combo Blood Pressure Pill Can Improve BP Control

Triple Combo Blood Pressure Pill Can Improve BP ...

Proportion achieving target BP increased with use of triple combo pill versus usual care at six months

is free, fast, and customized just for you!




Already a member?

Sign In Now »